Cargando…
Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome
Background: Recently, anti-PD-1 antibodies plus lenvatinib has been administered in a series of solid tumors. Yet, the efficacy of chemo-free treatment of this combined therapy has seldom been reported in gallbladder cancer (GBC). The aim of our study was to initially evaluate the efficacy of the ch...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252738/ https://www.ncbi.nlm.nih.gov/pubmed/37296684 http://dx.doi.org/10.3390/diagnostics13111833 |
_version_ | 1785056242464456704 |
---|---|
author | Wu, Tiantian Pu, Changsheng Wu, Xianjia Wang, Qiang Zhang, Keming |
author_facet | Wu, Tiantian Pu, Changsheng Wu, Xianjia Wang, Qiang Zhang, Keming |
author_sort | Wu, Tiantian |
collection | PubMed |
description | Background: Recently, anti-PD-1 antibodies plus lenvatinib has been administered in a series of solid tumors. Yet, the efficacy of chemo-free treatment of this combined therapy has seldom been reported in gallbladder cancer (GBC). The aim of our study was to initially evaluate the efficacy of the chemo-free treatment in unresectable GBCs. Methods: We retrospectively collected the clinical data of unresectable GBCs treated using chemo-free anti-PD-1 antibodies plus lenvatinib in our hospital from March 2019 to August 2022. The clinical responses were assessed, and PD-1 expression was evaluated. Results: Our study enrolled 52 patients, with the median progression-free survival being 7.0 months and the median overall survival being 12.0 months. The objective response rate was 46.2% and the disease control rate was 65.4%. The expression of PD-L1 in patients with objective response was significantly higher than those with progression of disease. Conclusions: For patients with unresectable GBC, when not eligible for systemic chemotherapy, chemo-free treatment using anti-PD-1 antibodies with lenvatinib may become a safe and rational choice. The expression of PD-L1 in tumor tissues may be correlated to the objective response, and thus is expected to be a predictor of efficacy, and further clinical studies are certainly needed. |
format | Online Article Text |
id | pubmed-10252738 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102527382023-06-10 Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome Wu, Tiantian Pu, Changsheng Wu, Xianjia Wang, Qiang Zhang, Keming Diagnostics (Basel) Article Background: Recently, anti-PD-1 antibodies plus lenvatinib has been administered in a series of solid tumors. Yet, the efficacy of chemo-free treatment of this combined therapy has seldom been reported in gallbladder cancer (GBC). The aim of our study was to initially evaluate the efficacy of the chemo-free treatment in unresectable GBCs. Methods: We retrospectively collected the clinical data of unresectable GBCs treated using chemo-free anti-PD-1 antibodies plus lenvatinib in our hospital from March 2019 to August 2022. The clinical responses were assessed, and PD-1 expression was evaluated. Results: Our study enrolled 52 patients, with the median progression-free survival being 7.0 months and the median overall survival being 12.0 months. The objective response rate was 46.2% and the disease control rate was 65.4%. The expression of PD-L1 in patients with objective response was significantly higher than those with progression of disease. Conclusions: For patients with unresectable GBC, when not eligible for systemic chemotherapy, chemo-free treatment using anti-PD-1 antibodies with lenvatinib may become a safe and rational choice. The expression of PD-L1 in tumor tissues may be correlated to the objective response, and thus is expected to be a predictor of efficacy, and further clinical studies are certainly needed. MDPI 2023-05-23 /pmc/articles/PMC10252738/ /pubmed/37296684 http://dx.doi.org/10.3390/diagnostics13111833 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wu, Tiantian Pu, Changsheng Wu, Xianjia Wang, Qiang Zhang, Keming Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome |
title | Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome |
title_full | Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome |
title_fullStr | Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome |
title_full_unstemmed | Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome |
title_short | Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome |
title_sort | chemo-free treatment using anti-pd-1 antibodies with lenvatinib in unresectable gallbladder cancer: pd-l1 may be a potential biomarker for a better outcome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252738/ https://www.ncbi.nlm.nih.gov/pubmed/37296684 http://dx.doi.org/10.3390/diagnostics13111833 |
work_keys_str_mv | AT wutiantian chemofreetreatmentusingantipd1antibodieswithlenvatinibinunresectablegallbladdercancerpdl1maybeapotentialbiomarkerforabetteroutcome AT puchangsheng chemofreetreatmentusingantipd1antibodieswithlenvatinibinunresectablegallbladdercancerpdl1maybeapotentialbiomarkerforabetteroutcome AT wuxianjia chemofreetreatmentusingantipd1antibodieswithlenvatinibinunresectablegallbladdercancerpdl1maybeapotentialbiomarkerforabetteroutcome AT wangqiang chemofreetreatmentusingantipd1antibodieswithlenvatinibinunresectablegallbladdercancerpdl1maybeapotentialbiomarkerforabetteroutcome AT zhangkeming chemofreetreatmentusingantipd1antibodieswithlenvatinibinunresectablegallbladdercancerpdl1maybeapotentialbiomarkerforabetteroutcome |